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ABSTRACT
Since it is impossible to recognize malignancy at fine needle aspiration (FNA) 
cytology in indeterminate thyroid nodules, surgery is recommended for all of them. 
However, cancer rate at final histology is <30%. Many different test-methods have 
been proposed to increase diagnostic accuracy in such lesions, including Galectin-3-
ICC (GAL-3-ICC), BRAF mutation analysis (BRAF), Gene Expression Classifier (GEC) 
alone and GEC+BRAF, mutation/fusion (M/F) panel, alone, M/F panel+miRNA GEC, 
and M/F panel by next generation sequencing (NGS), FDG-PET/CT, MIBI-Scan and 
TSHR mRNA blood assay.
We performed systematic reviews and meta-analyses to compare their features, 
feasibility, diagnostic performance and cost. GEC, GEC+BRAF, M/F panel+miRNA GEC 
and M/F panel by NGS were the best in ruling-out malignancy (sensitivity = 90%, 
89%, 89% and 90% respectively). BRAF and M/F panel alone and by NGS were the 
best in ruling-in malignancy (specificity = 100%, 93% and 93%). The M/F by NGS 
showed the highest accuracy (92%) and BRAF the highest diagnostic odds ratio 
(DOR) (247). GAL-3-ICC performed well as rule-out (sensitivity = 83%) and rule-in 
test (specificity = 85%), with good accuracy (84%) and high DOR (27) and is one of 
the cheapest (113 USD) and easiest one to be performed in different clinical settings.
In conclusion, the more accurate molecular-based test-methods are still 
expensive and restricted to few, highly specialized and centralized laboratories. 
GAL-3-ICC, although limited by some false negatives, represents the most suitable 
screening test-method to be applied on a large-scale basis in the diagnostic algorithm 
of indeterminate thyroid lesions.
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INTRODUCTION
Follicular thyroid nodules with indeterminate 
pattern at fine needle aspiration (FNA) cytology are called 
in different ways, according to the different classification 
systems adopted. They are classified as thy3a in the 
presence of atypical features and as thy3f when a follicular 
neoplasm is suspected, according to the British Thyroid 
Association (BTA) [1]. They are defined as category 
III (Atypia of Undetermined Significance [AUS] or 
Follicular Lesion of Undetermined Significance [FLUS]) 
and IV (Follicular Neoplasm [FN] or Suspicious for a 
Follicular Neoplasm [SFN]), according to the Bethesda 
system [2]. In Italy, the Italian Society of Endocrinology 
(SIE), the Italian Thyroid Association (AIT), the Italian 
Association of Clinical Endocrinologists (AME) and the 
Italian Society for Anatomic Pathology and Cytology joint 
with the Italian Division of the International Academy of 
Pathology (SIAPEC-IAP) adopt the term Tir3A for low-
risk and Tir3B for high-risk indeterminate lesions [3]. 
Independently of the classification system used, thyroid 
nodules classified in these categories represent the gray 
zone of conventional FNA-cytology [4, 5]. They are 
diagnosed in 15% - 30% of the total FNA cases and are 
currently referred for surgery more for diagnosis rather 
than for a real therapeutic necessity. Cancer prevalence in 
such indeterminate nodules varies according to the larger 
studies, performed in different Countries (Table 1).
Pooled mean value is 27.6% (95% CI ranging from 
26.4% to 28.7%). The lowest prevalence was reported in 
Boston, MA (11.1%, with 95% CI ranging from 6.5% to 
17.4%) [22]. The highest prevalence was registered in 
Table 1: Cancer prevalence in thyroid nodules with indeterminate cytology
Author Publication Year Nodules with Indeterminate Cytology (resected)
Cancers at Histology 
(n.)
Cancers at Histology 
(%) (95% CI)
Davis [6] 1991 395 152 38.5 (33.7-43.5)
Tuttle [7] 1998 103 22 21.4 (13.9-30.5)
Raber [8] 2000 120 21 17.5 (11.2-25.5)
Baloch [5] 2002 122 37 30.3 (22.3-39.3)
Kim [9] 2003 215 102 47.4 (40.6-54.3)
Sclabas [10] 2003 100 27 27.0 (18.6-36.8)
Giorgadze [11] 2004 169 76 45.0 (37.3-52.8)
Pu [12] 2006 303 87 28.7 (23.7-34.2)
Wu [13] 2006 172 52 30.2 (23.5-37.7)
Yassa [14] 2007 352 94 26.7 (22.1-31.6)
Yang [15] 2007 378 100 26.5 (22.1-31.2)
Oertel [16] 2007 391 103 26.3 (22.0-31.0)
Mihai [17] 2009 201 57 28.4 (22.2-35.1)
Banks [18] 2008 489 145 29.7 (25.6-33.9)
Theoharis [19] 2009 129 48 37.2 (28.9-46.2)
Sorrenti [20] 2009 603 106 17.6 (14.6-20.9)
Asari [21] 2010 156 55 35.3 (27.8-43.3)
Lubitz [22] 2010 144 16 11.1 (6.5-17.4)
Rago [23] 2014 1,520 371 24.4 (22.3-26.6)
Pooled 6,062 1,671 27.6 (26.4-28.7)
Major studies (more than 100 cases) published in the literature concerning the occurrence of thyroid malignancy in 
indeterminate thyroid nodules. Data have been extrapolated by considering only tir3A/Tir3B/thy3a/thy3f/AUF/FLUS/FN/
SFN cases. In all studies patients that received a cytological diagnosis of indeterminate thyroid nodules were surgically 
treated and histologically verified. Percentages of malignancy at histology, with corresponding 95% CI, are reported.
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South Korea (47.4%, with 95% CI ranging from 40.6% 
to 54.3%) [9]. In Italy the prevalence of malignancy in 
this type of nodules was 24.4% (95% CI ranging from 
22.3% to 26.6%) and it didn’t change over the time 
[23, 24], despite the increased incidence of thyroid 
cancer of 4.3% per year reported in the Italian general 
population [25, 26]. This means that about 70% of such 
indeterminate thyroid lesions that are referred to surgery 
are over-treated. Many different attempts have been made 
to ameliorate the accuracy of thyroid FNA-cytology by 
using clinical, ultrasonographic and scintigraphic features, 
but none of them proved to be accurate enough [27–29], 
even when a novel scoring system that combines and 
integrates the cytological information with the clinical and 
ultrasonographic risk factors of malignancy is used [30]. 
Several different test-methods have been proposed so far. 
They include new emerging molecular-based diagnostic 
tests, directly performed on thyroid FNA samples [31] 
or assay performed on peripheral blood [32], as well as 
nuclear medicine imaging tests, using tracers that are 
absorbed (“hot”) or excluded (“cold”) by the nodule, 
to detect thyroid malignancy [33–35] and expression 
analysis of putative protein tumor-associated markers, 
directly performed on thyroid FNA samples [31]. Both 
ATA Guidelines Task Force on Thyroid Nodules and 
Differentiated Thyroid Cancer [4] and NCCN Tumor 
Marker Task Force [36] suggested that the clinical utility 
of a molecular test should be founded in strong evidence 
proving that use of the marker “improves patient outcomes 
sufficiently to justify its incorporation into routine clinical 
practice” and it should not be intended to replace other 
sources of information or clinical judgment. The most 
extensively studied genetic marker is represented by 
a mutation of the BRAF gene. The specific mutation 
consists in a T1799A transversion resulting in a V600E 
amino acid substitution, with subsequent constitutive 
activation of BRAF kinase. The potential diagnostic and 
prognostic value of this genetic marker is proved by many 
studies [37, 38]. The diagnostic relevance of such marker 
is also demonstrated by the fact that it is included in all 
the composite molecular genetic panels proposed so far 
for recognizing thyroid malignancy in indeterminate 
thyroid nodules. Among the various thyroid cancer protein 
markers, Galectin-3 represents one of the most extensively 
studied. Galectin-3 is a multifunctional molecule involved 
in regulation of apoptosis [39, 40] whose potential role as 
a thyroid cancer marker was recognized by many studies 
since the first report published in 1995 [41]. A test-method 
based on Galectin-3 immunocytochemistry (GAL-3-ICC) 
analysis on thyroid FNA samples, named ThyroTest, has 
been developed and validated for clinical use in two large 
multicenter studies [42, 43] as well as in many others 
studies in different Countries [44].
The availability of so many different diagnostic 
tools for the preoperative characterization of thyroid 
nodules with indeterminate cytology urgently demands 
a comparative analysis of their diagnostic performance, 
feasibility, cost and effectiveness. Such a comparison, 
based on data collected in different clinical settings of 
various geographical and socio-economical contexts and 
involving diverse laboratory expertise, may be extremely 
challenging. For a more accurate comparative analysis the 
same indeterminate thyroid nodule population should be 
investigated by different test-methods. Recently, some 
attempts have been made to compare in the same nodule 
population some of the available test-methods [45–48]. 
The present extensive comparative analysis includes many 
different histopathological, genetic and imaging biomarkers 
and is aimed to provide to clinicians key information for 
a more cost-conscious clinical management of patients 
bearing indeterminate thyroid nodules. We considered 
the following test-methods: GAL-3-ICC, BRAF mutation 
analysis, GEC methods alone (Afirma® GEC by Veracyte) 
and in conjunction with BRAF mutation detection 
(Afirma® GEC + BRAF by Veracyte), thyroid cancer 
M/F panel (miRInform™ by Asuragen, and by Quest 
Diagnostics and ThyGenX® by Interpace Diagnostic), 
alone and in conjunction with miRNA GEC (ThyGenX® 
+ ThyraMIR™) and thyroid cancer M/F panel analyzed 
by next generation sequencing (NGS) (Thyroseq® v.2 by 
CBLPath), [18F]-2-fluoro-2-deoxy-d-glucose–positron-
emission-tomography/computed-tomography (FDG-
PET/CT), [99mTc]-methoxyisobutylisonitrile scintigraphy 
(MIBI-Scan) and TSHR mRNA blood assay. A systematic 
literature search was performed for each one of them. 
According to established criteria, the most representative 
studies published from 2000 to 2016 were selected. We 
focused our attention to analyze the cancer prevalence of 
the population examined, the technical methodology used, 
the feasibility, the cost and the diagnostic performance 
of each one of test-method included in the study. Data 
regarding the various indicators of diagnostic performance 
and of the cost for each one of them were used to perform 
a comparative statistical analysis.
RESULTS
Characteristics of the included studies
A total of 45 different studies were selected on the 
basis of the criteria described in Materials and Methods 
section and following current protocols and guidelines 
[49]. The search strategy and the flow of information 
of our systematic review are reported in Figure 1. The 
features of the studies that met all the inclusion criteria 
are summarized in Table 2.
Selected studies were performed in different 
geographical areas and in different Institutions. The 
specific features and test outcome, according to the 
gold standard of final histology, are reported. Patients 
were enrolled either in Academic Medical Centers, in 
University Hospitals or in private companies. In some 
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Figure 1: Flow of information of our systematic review for each test-method, through the four-phase flow, according 
to the PRISMA statement.
studies, the test was performed in two subsequent periods, 
by the same Academic Medical Center in U.S.A. [32, 50]. 
In others, patients were enrolled in thyroid Centers of 
different Countries, such as U.S.A. [51–54, 59], Denmark 
[55], Canada [56], China [57] and Italy [58], and the 
samples were referred to a single central laboratory for 
molecular analysis. In other studies the same population of 
thyroid nodules, analyzed with one test was also subjected 
to another additional test [54, 61]. There are differences 
regarding also the total number of cases examined in these 
studies. In three test-methods, namely the BRAF mutation 
analysis [46, 51–53, 56–58, 63–79], the M/F panel [51–
58] and the GAL-3-ICC [43, 78, 80–86], more than 1,000 
cases from different studies were pooled together. In the 
case of the other six test-methods, the GEC alone [60], 
the GEC plus BRAF [61], the M/F panel plus miRNA 
GEC [54], the M/F panel by NGS [59], the TSHR mRNA 
[32, 50] and MIBI-scan [34, 35, 46], more than 100 cases 
were retrieved and pooled together. Finally, in the case of 
FDG-PET/CT [62] only slightly more than 50 cases were 
analyzed from one single study. The cancer prevalence 
reported in the selected studies ranged from 20% to 44%, 
and was in line with that reported in the literature for 
indeterminate nodules (Table 1).
Assessment of study heterogeneity
In 4 test-methods, namely the BRAF mutation 
analysis, GAL-3-ICC, MIBI-Scan and M/F panel, the 
systematic literature search, based on the established 
criteria, allowed us to select multiple studies, suitable to 
perform a meta-analysis. The graphical representations 
of these four meta-analyses are visualized in Figure 
2. In the forest plot of GAL-3-ICC and MIBI-Scan no 
overlapping of the vertical line, corresponding to odds 
ratio = 1, with the confidence intervals of all studies was 
observed, indicating that all these studies are significant at 
5% level. The same vertical line (odds ratio = 1) overlaps 
the confidence intervals of 7 out of 24 studies in BRAF 
mutation analysis, and of 2 out of 8 studies in M/F panel, 
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indicating that these studies were less significant. In the 
forest plot of BRAF mutation, the last study [46] was 
excluded from the analysis because statistical calculations 
were not feasible. In that study, in fact, no positive results, 
either true or false, were reported. The I-squared (I2) was 
measured for the selected studies of each test-method to 
evaluate study heterogeneity. The overall I2 was 0% in the 
BRAF group, indicating that inconsistency across studies 
may not be important. The overall I2 was 39.7% in MIBI-
Scan group and 68.7% in GAL-3-ICC group, indicating 
occurrence of moderate heterogeneity. Finally, The overall 
I2 was 84% in the M/F panel group, suggesting occurrence 
of substantial heterogeneity.
Tests classified according to their ability to 
exclude (rule-out) malignancy
The ability of a negative diagnostic test-method to 
exclude malignancy in a thyroid nodule with indeterminate 
cytology would be extremely useful in surgical decision-
Table 2: Characteristic of the studies included in the comparative analysis
Test-methods 
to Select Thy-3 
nodules for 
surgery
GAL-3-ICC
BRAF 
Mutation 
Analysis
Gene Expression Classifier 
(GEC) Mutation/Fusion panel
FDG-
PET/CT MIBI-Scan
TSHR 
mRNA AssayGEC 
(Veracyte 
Afirma®)
GEC + BRAF 
(Veracyte 
Afirma® + 
BRAF)
Mutation/Fusion 
panel (Asuragen 
miRInform™, 
Quest Diagnostic & 
Interpace Diagnostic 
ThyGenX®)
Mutation/Fusion 
panel + miRNA 
GEC (Interpace 
Diagnostic 
ThyGenX®/
ThyraMIR™)
Mutation/
Fusion 
panel 
by NGS 
(Thyroseq 
Ver. 2.0)
Bio-molecular 
Marker Type
Protein 
(Galectin-3)
DNA (1 
gene, 1 
codon)
RNAs (167 
genes)
RNAs & 
DNAs (167 
genes) + 
BRAF 
mutation
RNAs and DNAs 
(4 genes, 14 SNPs 
and 3 chromosome 
rearrangements)
RNAs and DNAs 
(4 genes, 14 SNPs 
& 3 chromosome 
rearrangements) + 
10 miRNA
RNAs & 
DNAs (13 
genes and 
42 gene 
fusions)
Glucose 
uptake
Sesta-MIBI 
uptake TSHR mRNA
Method Immuno-
CytoChemistry
BRAF 
(V600E) 
mutation 
analysis
Gene 
Expression 
Classifier
Gene 
Expression 
Classifier 
+ BRAF 
(V600E) 
mutation 
analysis
RT-PCR, 
Fluorescence Melting 
Curve, Luminex, 
Sanger sequencing, 
Pyrosequencing
RT – qPCR 
Luminex
Next 
Generation 
Sequence 
(NGS)
FDG-
PET/CT
Thyroid 
Scintigraphy 
(visual 
analysis)
qRT -PCR 
Blood Assay
Patients 
and samples 
recruitment
Pooled from 9 
studies
Pooled from 
24 studies
Multicenter (49, USA)
Multicenter (USA, 
Denmark, Italy) 
Pooled from 8 studies
Multicenter (USA) 1 Center 
(USA)
Pooled from 
3 studies 
(Italy)
Pooled from 2 
studies (USA)
Laboratory for 
Testing
9 Centers 
(Europe and 
Chile)
24 Centers 
(Europe, 
Canada, 
USA, China, 
Korea)
1 Center (USA) 1 Center (USA) 1 Center 
(USA)
3 Centers 
(Italy)
1 Center 
(USA)
Total number of 
cases 1,266 2,625 210 165 1,141 109 143 51 217 114
Cancer 
Prevalence (%) 
(95% CI)
33  
(30.9-36.2)
45  
(42.8-46.6)
24  
(18.6-30.7)
27  
(20.0-34.1)
24  
(21.7-26.7)
32  
(23.5-41.7)
27  
(20.2-35.3)
20  
(9.82-33.1)
29  
(23.1-35.6)
44  
(34.6-53.5)
True Positive 
(TP) eqv. with 
hit
351  
(27.7%)
474  
(18.1%)
46  
(21.9%)
39  
(23.6%)
141  
(12.4%)
31  
(28.4%)
35  
(24.5%)
8 
(15.7%)
42  
(19.4%)
35  
(30.7%)
True Negative 
(TN) eqv. with 
correct rejection
716  
(56.6%)
1,451 
(55.3%)
82  
(39.0%)
60  
(36.4%)
805  
(70.6%)
63  
(57.8%)
97  
(67.8%)
25 
(49.0%)
129  
(59.4%)
52  
(45.6%)
False Positive 
(FP) eqv. with 
false alarm
127  
(10.0%)
4  
(0.1%)
77  
(36.7%)
61  
(37.0%)
61  
(5.3%)
11  
(10.1%)
7  
(4.9%)
16 
(31.4%)
25  
(11.5%)
12  
(10.5%)
False Negative 
(FN) eqv. with 
miss
72  
(5.7%)
696  
(26.5%)
5  
(2.4%)
5  
(3.0%)
134  
(11.7%)
4  
(3.7%)
4  
(2.8%)
2 (3.9%)
21  
(9.7%)
15  
(13.2%)
Reference
[43, 78, 
80–86]
[46, 51–53, 
56–58, 
63–79]
[60] [61] [51–58] [54] [59] [62] [34, 35, 46] [32, 50]
Comparison of the seven different test-methods and their variants, proposed for the same diagnostic purpose in thyroid nodules with indeterminate cytology. The type of bio-
molecular marker, the method used, the total number of cases examined and the type of the study are also indicated. For each test-method the cancer prevalence, with 95% CI, 
and the results are reported.
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making, contributing to promptly identify those benign 
lesions that can be directed to follow-up. We therefore 
classified the different diagnostic test-methods analyzed 
based on this ability (Table 3).
The best rule-out indicator is the sensitivity 
(“positivity in disease”) that refers to the proportion of 
subjects who have the target condition (malignancy at 
histology) and gives a positive test result. It corresponds 
to a high NPV and a low FNR. The present comparative 
analysis indicates that among all test-methods considered 
M/F panel by NGS, GEC alone, GEC + BRAF and M/F 
panel + miRNA GEC showed the highest sensitivities 
(90%, 90%, 89% and 89% respectively), the highest NPV 
(96%, 94%, 92% and 94% respectively), and the lowest 
FNR (10%, 10%, 11% and 11% respectively). These 
four test-methods appear, indeed, to be the most reliable 
ones for cancer exclusion (best rule-out methods). GAL-
3-ICC and FDG-PET/CT were both characterized by 
high sensitivity (83% and 80% respectively), high NPV 
(91% and 93% respectively), with a low, but significant 
FNR (17% and 20% respectively) and cancer risk in 
negative lesions (9% and 7% respectively). TSHR mRNA 
blood assay, and MIBI-Scan showed a lower sensitivity 
(70% and 67% respectively), a lower NPV (78% and 
86% respectively) and a higher FNR (30% and 33% 
respectively). The BRAF mutation analysis showed 
the lowest sensitivity among all tests (41%), the lowest 
NPV (68%) and the highest FNR observed (59%). The 
diagnostic performance of this test-method in excluding 
malignancy didn’t improve much even if it was integrated 
with the analysis of a panel of thyroid specific M/F gene 
alterations. The use of M/F panel, in fact, yields only a 
slight increase in sensitivity (51%), of NPV (86%), a 
slightly reduced, but still elevated FNR (49%) as well as 
a high cancer risk in negative lesions (14%). Therefore, 
BRAF Mutation analysis and M/F panel are not adequate 
to efficiently exclude malignancy (worst rule-out 
methods).
Tests classified according to their ability to detect 
(rule-in) malignancy
The ability of identifying malignancy among 
indeterminate thyroid nodules represents an important 
clinical achievement. Surgical decision based on a good 
rule-in test may lead clinicians to selectively refer to 
Figure 2: Forest plots of individual studies and pooled odds ratio of the four test-methods for which more then 2 
studies were selected from the systematic literature search. For each study the 95% confidence interval (95% CI) and the weight 
(%) were also reported. The open diamond at the bottom of the graph shows the average effect size of the examined studies.
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Table 3: Test methods classified according their ability in ruling-out or ruling-in malignancy, to their diagnostic 
performance and their cost
Test-methods 
to Select Thy-
3 nodules for 
surgery
GAL-3- 
ICC
BRAF 
Mutation 
Analysis
Gene Expression 
Classiifer (GEC) Mutation/Fusion panel
FDG-PET/
CT MIBI-Scan
TSHR 
mRNA 
Assay
GEC 
(Veracyte 
Afirma®)
GEC + 
BRAF 
(Veracyte 
Afirma® + 
BRAF)
Mutation/Fusion 
panel (Asuragen 
miRInform™, 
Quest Diagnostic & 
Interpace Diagnostic 
ThyGenX®)
Mutation/Fusion 
panel + miRNA 
GEC (Interpace 
Diagnostic 
ThyGenX®/
ThyraMIR™)
Mutation/
Fusion panel 
by NGS 
(Thyroseq 
Ver. 2.0)
A-Rule-out cancer
Sensitivity 
(%) (95% CI)
83  
(79.8-85.8)
41  
(39.9-40.7)
90  
(79.1-96.3)
89  
(76.3-95.6)
51  
(46.9-55.2)
89  
(75.6-96.0)
90  
(78.4-96.2)
80  
(47.3-96.4)
67  
(56.2-75.6)
70  
(59.3-78.6)
Negative 
Predicted 
value (NPV) 
(%)
91 68 94 92 86 94 96 93 86 78
Cancer 
risk rate in 
negative test 
(%)
9 32 6 8 14 6 4 7 14 22
False 
Negative Rate 
(FNR) (%)
17 59 10 11 49 11 10 20 33 30
Negative 
Likelihood 
Ratio (LR-) 
(95% CI)
0.2  
(0.16-0.24)
0.6  
(0.59-0.6)
0.19  
(0.07-0.44)
0.23  
(0.08-0.52)
0.52  
(0.47-0.58)
0.13  
(0.04-0.31)
0.11  
(0.04-0.24)
0.33  
(0.06-0.99)
0.4  
(0.28-0.55)
0.37  
(0.24-0.56)
B-Rule-in cancer
Specificity 
(%) (95% CI)
85  
(83.3-86.3)
100  
(99.3-100.0)
52  
(48.0-53.5)
50  
(45.1-52.1)
93  
(91.6-94.2)
85  
(79.0-88.6)
93  
(89.0-95.7)
61  
(53.0-65.0)
84  
(79.5-87.4)
81  
(72.9-88.0)
Positive 
Predicted 
value (PPV)
73 99 37 39 70 74 83 33 63 74
False Positive 
Rate (FPR) 
(%)
27 0 48 50 7 15 7 39 16 19
Positive 
Likelihood 
Ratio (LR+) 
(95% CI)
6  
(4.79-6.29)
147  
(53.8-461.5)
2  
(1.52-2.07)
2  
(1.39-2.61)
7  
(5.58-9.53)
6  
(3.60-8.45)
13  
(7.14-22.36)
2  
(1.00-2.75)
4  
(2.74-6.02)
4  
(2.18-6.53)
C-Diagnostic Performance
Accuracy (%) 
(95% CI)
84  
(82.2-86.2)
73  
(72.8-73.5)
61  
(55.6-63.9)
60 
(53.4-63.7)
83  
(80.8-84.8)
86  
(77.9-91.0)
92  
(86.1-95.8)
65  
(51.9-71.1)
79  
(72.7-84.0)
76  
(66.9-83.9)
F1 score (%) 78 58 53 54 59 81 86 47 65 72
Diagnostic 
Odds Ratio 
(DOR)
27 247 10 8 14 44 121 6 10 10
D-Single Test Cost
Single Test 
cost (USD) 113 97.45 3,200 3,675 2,250 3,300 3,200 1,132 1,648 300
Reference
[43, 78, 
80–86]
[46, 51–53, 
56–58, 
63–79]
[60] [61] [51–58] [54] [59] [62] [34, 35, 46] [32, 50]
A. Tests classified according to their ability to exclude malignancy (rule-out tests). B. Tests classified according to their 
ability to detect malignancy (rule-in tests). C. Tests classified according to their diagnostic performance. D. Tests classified 
according to their costs in USD.
For each test the 95% CI of sensitivity, specificity, accuracy, LR+ and LR- is reported in brackets.
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surgery only thyroid cancers, reducing the over-treatments 
of benign lesions and consequently the social costs. The 
test-methods were then classified according to this ability 
(Table 3). The best rule-in indicator is the specificity 
(“negativity in health”) that refers to the proportion of 
subjects without the target condition (malignancy at 
histology) and gives negative test results. It corresponds 
to high PPV and low FPR. There are many test-methods 
that proved to be good in detecting malignancy among 
the indeterminate thyroid follicular lesions. The best 
rule-in method is the BRAF mutation analysis. It showed 
an absolute specificity (100%) an almost absolute PPV 
(99%), with no occurrence of false positives (FPR = 0%). 
Many test-methods were characterized by a very high 
specificity (≥ 85%), namely the three variants of M/F 
panel-based test-methods (alone, + miRNA GEC and by 
NGS) and the GAL-3-ICC. They showed also a high PPV 
value (70%, 74%, 83% and 73% respectively) and a low 
FPR (7%, 15%, 7% and 27% respectively) (Table 3). 
Adjunction of the miRNA GEC to the M/F panel didn’t 
seem to increase the ability of this method in identifying 
malignancy and the combination of these two methods, 
compared to the M/F panel alone displayed a slightly 
reduction in specificity (85%) and moderate increase in 
NPV (74%), with a higher FPR (15%). The MIBI-Scan 
and the TSHR mRNA showed a lower specificity (84% 
and 81% respectively), with a lower PPV (63% and 74% 
respectively), and a rather higher FPR (16% and 19% 
respectively). The FGD-PET/CT was characterized by 
a very low specificity (61%), the lowest PPV observed 
(33%) and a very high FPR (39%). GEC method, alone 
or in combination with BRAF mutation detection, 
didn’t show a good rule-in performance, with the lowest 
specificity (52% and 50% respectively), a rather low PPV 
(37% and 39% respectively) and with the highest FPR 
(48% and 50% respectively). Both GEC alone and GEC 
+ BRAF mutation analysis, therefore, appear to be not 
reliable for cancer detection (worst rule-in tests).
Tests classified according to their combined 
ability to detect (rule-in) and to exclude (rule-
out) malignancy
Sensitivity and specificity of all test-methods 
analyzed were graphically expressed in a two-dimensional 
scatterplot diagram (Figure 3). FDG-PET/CT and GEC 
alone or in conjunction with BRAF mutation analysis, 
all characterized by high sensitivity (upper part of the 
diagram), showed a rather low specificity (left part of 
the panel). Many different test-methods reached very 
high specificity and are consequently plotted at the very 
right extremity of the diagram. However, they showed 
different levels of sensitivity. In the cases of the BRAF 
mutation analysis an absolute specificity (right-most 
side of the diagram) was associated with a rather low 
sensitivity (lowest part of the diagram). The M/F panel 
alone also showed a combination of high specificity (right 
extremity of the diagram) and low sensitivity (lower part 
of the diagram). The MIBI-Scan and TSHR mRNA were 
plotted in the lower part of the diagram, with their low 
Figure 3: Comparative two-dimensional scatterplot diagram of sensitivity and specificity of each test-method. Arbitrary 
cut-off lines at 80% of specificity and at 80% of sensitivity were included in the diagram.
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sensitivities, combined with slightly better specificities. 
The adjunction of the miRNA GEC analysis to the M/F 
panel or its analysis by NGS greatly improved the 
sensitivity of this method and contributed to locate these 
two methods in the upper right part of the diagram. The 
M/F by NGS reached the best combination of sensitivity 
and specificity among all the test-methods analyzed. 
GAL-3-ICC showed equally good levels of sensitivity and 
specificity and is plotted in the most favorable upper right 
part of the diagram.
Tests classified according to their likelihood 
ratios
In the decision process among competing diagnostic 
test-methods in a clinical application the use of positive 
and negative likelihood ratios, rather than simple value 
of sensitivity and specificity, as measures of diagnostic 
ability has been recommended [87]. Likelihood ratios 
have a number of useful properties, including the fact 
that they do not vary in different populations or settings 
and are independent of prevalence of the disease [88]. 
They are generally considered one of the best ways to 
measure and express diagnostic accuracy [89]. Larger 
values of LR+ and smaller values of LR- indicate greater 
diagnostic ability (discrimination ability). Therefore, when 
choosing a diagnostic test, one would prefer those with 
LR+ as high as possible and, simultaneously, with LR- 
as low as possible [87]. Data concerning LR+ and LR- 
values of the different test-methods are reported in Table 
3 and visualized in Figure 4. Usually a value of LR+ >5 
indicates that the test result has a moderate/large effect on 
increasing the probability of disease, while value of LR+ 
<5 indicates a small effect on increasing the probability 
of disease. On the other side, an LR- <0.3 indicates that 
the result has a large/moderate effect on decreasing the 
probability of disease presence, while a value of LR- >0.3 
indicates a small effect on decreasing disease probability. 
The present comparative analysis indicates that some test-
methods such as FDG-PET/CT, MIBI-Scan and TSHR 
mRNA, showed the unfavorable combination of very low 
LR+ and a high LR- and are plotted on the lower right part 
of the diagram. The test-methods that showed the most 
favorable combination of high LR+ and low LR- are the 
M/F panel by NGS, the M/F panel + miRNA GEC and 
the GAL-3-ICC, all plotted in the left upper part of the 
diagram. The two test-methods that were characterized 
by high LR+ and high LR- are BRAF mutation and M/F 
Figure 4: Comparative two-dimensional scatterplot diagram of LR+ and LR- of each test-method. (LR+ Positive 
Likelihood Ratio, LR- Negative Likelihood Ratio). Arbitrary cut-off lines at 5 of LR+ and at 0.3 of LR- were included in the diagram.
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panel alone. In particular, the BRAF mutation was the 
method with the highest value of LR+ (out of scale in the 
diagram), combined, however, with the highest LR- value. 
Finally the GEC method alone and GEC + BRAF showed 
a low LR- combined with a low LR+.
Tests classified according to their diagnostic 
performance
Three different parameters, all related to the ability 
to discriminate between benign and malignant thyroid 
nodules were measured, namely the accuracy, the F1 
score and the DOR (Table 3). The test-method with the 
best accuracy is the M/F panel by NGS (92%), followed 
by M/F + miRNA GEC (86%), by GAL-3-ICC (84%) and 
by M/F panel alone (83%). The diagnostic accuracy of the 
remaining test-methods, namely the MIBI-Scan (79%), the 
TSHR mRNA (76%), the BRAF mutation analysis (73%), 
the FDG-PET/CT (65%), the GEC (61%) and the GEC+ 
BRAF (60%) were the lowest among all test-methods 
considered. We then classify the test-methods according 
to their F1 score, which equally weights recall (ratio of 
true positives to all actual positives) and precision (ratio of 
true positives to all predicted positives) and illustrates the 
overall accuracy of a test. According to this calculation, 
M/F panel by NGS and M/F panel + miRNA GEC were 
the two best test-methods among all. They showed, in 
fact, an F1 score of 86% and 81% respectively. GAL-3-
ICC ranked among the top ones (78%), followed by the 
TSHR mRNA (72%) and the MIBI-Scan (65%). The M/F 
panel alone (59%), the BRAF mutation analysis (58%), 
both GEC test-methods, alone (53%) or + BRAF (54%), 
and the FDG-PET/CT (47%) showed the lowest F1 score 
among all. When test-methods were analyzed using the 
DOR we observed that the best value was obtained by 
BRAF mutation analysis (247), followed by M/F panel 
by NGS (121) and by M/F panel + miRNA GEC (44). 
GAL-3-ICC showed a good DOR (27). A lower DOR 
was measured for M/F panel alone (14), GEC alone (10), 
TSHR mRNA (10) and MIBI-Scan (10), while the lowest 
values were observed for GEC + BRAF (8) and FGD-
PET/CT (6).
Tests classified according to their cost, 
effectiveness and feasibility
In the effort to control expenses we focused our 
attention not only on the possible benefits, practical 
feasibility and the diagnostic value of each test-method 
but also on the single test cost and, hence, the estimated 
costs for the community. Costs were expressed as 2016 
USD (1 USD = 1,1306 Euro) [90]. A comparative analysis 
of the costs is shown in Table 3. All molecular based test-
methods require the use of sophisticated instruments and 
reagents by specialized physicians in centralized well-
equipped molecular laboratories and that is the reason 
why they are very expensive. In particular, the cost of each 
single GEC test was the highest one (3,200 USD/test) and 
the cost for a single M/F panel-based was 2,250 USD/test 
for Quest Diagnostic, 1,675 USD/test for ThyGenX® alone 
and 4,975 USD/test for the combination of ThyGenX® + 
ThyraMIR™. Compared to these molecular approaches, 
GAL-3-ICC is by far one of the cheapest, with its cost of 
113 USD/test. Moreover GAL-3-ICC analysis is easy to be 
performed in any clinical context, in which a conventional 
surgical pathology laboratory is equipped to provide an 
immuno-cyto/histochemistry service. This assay integrates 
the diagnostic performance of conventional thyroid FNA-
cytology and use the same cell substrates, which can 
be morphologically classified. Methods and reagents 
for GAL-3-ICC have been standardized for clinical use 
[91]. TSHR mRNA blood assay and BRAF mutation 
analysis are also cheap with their costs of 97.45 USD/
test and 300 USD/test respectively. Unlike the other test-
methods, TSHR mRNA blood assay doesn’t require an 
FNA sampling of the thyroid nodule. The average cost 
of FDG-PET/CT is 1,132 USD/test [92] and it is similar 
to that for MIBI-Scan (1,648 USD/test) [48]. Both these 
procedures can only be performed in a highly specialized 
radiology and nuclear medicine Units, and they expose 
patients to radiations, that can be reduced if only the 
thyroid bed is scanned. However, for these reasons they 
are not recommended as routine screening methods. The 
comparative combined analysis of cost and effectiveness 
of the test-methods included in the study was conducted 
using both the two-dimensional (Figure 5) and the three-
dimensional scatterplot diagrams (Figure 6). In the two-
dimensional diagram the most accurate test-methods are 
plotted on the right part and the cheapest on the lower 
part of the diagram. GAL-3-ICC is the only test method 
to be plotted in the most favorable lower right part of 
the diagram, showing the best combination of high 
accuracy (84%) and low cost (113 USD/test). Cost and 
effectiveness of this procedure is optimal and, therefore, it 
represents a suitable screening method for the preoperative 
characterization of indeterminate thyroid nodules on a 
large-scale basis. BRAF mutation analysis and TSHR 
mRNA blood assay also ranked as cheap test-methods 
(97.45 USD/test and 300 USD/test respectively), but they 
showed lower accuracy rate (73% and 76% respectively) 
and they are, therefore, both plotted in the left lower 
part of the diagram. The three methods based on M/F 
panel analysis were located in the upper right part of the 
diagram, indicating an excellent accuracy but a high cost. 
Among them the one that is based on the NGS technique 
showed the best accuracy (92%), but its cost was rather 
high (3,200 USD/test). The two test-methods based on 
GEC analysis are both located in upper left part of the 
diagram, indicating a rather unsatisfactory combination 
of low accuracy and high cost, compared to the other 
test-methods analyzed. FDG-PET/CT and MIBI-Scan 
showed a combination of intermediate values of both 
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Figure 5: Comparative two-dimensional scatterplot diagram of cost and accuracy of each test-method. Arbitrary cut-off 
lines at 80% of accuracy and at 1,000 and 2,000 USD were included in the diagram.
Figure 6: Comparative three-dimensional scatterplot diagram of cost, sensitivity and specificity of each test-method. 
Arbitrary cut-off lines at 80% of sensitivity, at 80% of specificity and at 1,500 of single test cost, expressed in USD, were included in the 
diagram.
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accuracy (65% and 79% respectively) and cost (both tests 
> 1,000 USD and < 2,000 USD). To better analyze the 
effectiveness and cost sensitivity, specificity and cost of 
each single test was visualized on a three-dimensional 
scatterplot diagram (Figure 6). The diagram indicates that, 
as previously observed, the two molecular test-methods 
characterized by very high sensitivity, namely GEC alone 
and GEC + BRAF, do not combine this favorable feature 
with a correspondingly high specificity and, in addition, 
they are among the most expensive ones. For this reason 
they are plotted in the left/posterior/high sector of the 
3D diagram. BRAF mutation, characterized by absolute 
specificity and low sensitivity, is one of the cheapest ones 
and is, therefore, plotted in right/anterior/low sector of the 
3D diagram. M/F panel based test-methods, especially the 
one analyzed by NGS and the M/F panel + miRNA CEG, 
reached an excellent combination of very high sensitivity 
and very high specificity. However, the clinical use of all 
these molecular-based test-methods is hampered by its 
very high cost. FDG-PET/CT and MIBI-Scan are both 
characterized by a medium cost of each single exam. 
However, MIBI-Scan showed a slightly better specificity, 
while FDG-PET/CT was characterized by a slightly 
better sensitivity. The test-method that showed the best 
combination of high sensitivity, high specificity and low 
cost is the GAL-3-ICC, characterized, in fact, by good 
specificity (85%) and sensitivity (83%), combined with 
a very low cost (113 USD). This test-method, the only 
one that is plotted in the anterior and lower part of the 3D 
diagram, appears to be suitable to be chosen as a screening 
test on large-scale basis.
Proposed diagnostic algorithm for indeterminate 
thyroid nodules
Based on the results of our comparative analysis 
we propose an algorithm that includes cytology and other 
ancillary test-methods in the management of patients with 
thyroid nodules (Figure 7). The advantage of this algorithm 
relies in the reduction of unnecessary surgery by means of 
a first level, low-cost test-method, which can be integrated, 
in selected cases, with a second-level high-cost molecular-
based test-method. In fact, on the basis of our comparative 
data, we believe that patients with indeterminate thyroid 
nodules should be initially considered for GAL-3-ICC, a 
low-cost procedure that proved to be sufficiently highly 
sensitive and specific. Thyroid nodules with indeterminate 
cytology that were positive at GAL-3-ICC analysis should 
be considered for surgery, while GAL-3-ICC negative 
ones can be monitored by repeated ultrasonographic 
evaluation, without surgery, as recently suggested [93]. 
Molecular-based test-methods should be considered as 
second-line tests, appropriate in high-income Countries 
where highly specialized molecular genetics laboratory 
are available. In GAL-3-ICC-positive nodules the use of 
a more efficient rule-in test, such as M/F panel by NGS, 
would be useful to confirm malignancy and to better 
plan the extent of thyroidectomy. Conversely, in GAL-
3-ICC-negative nodules the use of a more efficient rule-
out test, such as GEC, would allow a better and prompt 
identification of the possible GAL-3-ICC false negative 
results. The use of GAL-3-ICC was also proposed in 
suspicious for malignancy thyroid nodules, in association 
with HBME-1, to reduce surgical risk especially in elderly 
patients with advanced age and co-morbidities [86]. A 
detailed cost-effectiveness analysis of the GAL-3-ICC is 
needed to compare results obtained with either GEC [94] 
or M/F panel [95], both characterized by a favorable cost-
effectiveness profile when compared to standard of care 
and, in particular, to surgery. The real cost-effectiveness of 
the proposed algorithm also remains to be systematically 
analyzed.
DISCUSSION
Preoperative characterization of thyroid nodules is 
one of the major problems in the clinical practice [96]. 
Thyroid FNA-cytology consistently improved 
preoperative cancer detection but the finding of 
indeterminate follicular lesions still represents an area of 
ambiguity [97]. Clinical criteria, ultrasonography as well 
as scintigraphy, should always be considered in the 
management of such nodules, but they are not accurate 
enough in ruling-in or ruling-out thyroid malignancies, 
because their unfavorable likelihood ratios [28, 98, 99]. 
Founded on these criteria, many unnecessary surgical 
procedures are still performed to remove benign lesions 
[29, 100–103]. The real innovation in this field, however, 
is the availability of new techniques, designed to identify 
specific genetic and epigenetic markers of thyroid 
malignancy. Whether their accuracy is good enough to 
significantly ameliorate diagnosis and treatment of such 
patients and, most important, to justify their cost is an 
open question. The AACE Thyroid scientific Committee 
evaluated these molecular test-methods, together with a 
TSHR mRNA blood assay, and stated that, these diagnostic 
approaches cannot replace the traditional clinical, US and 
cytopathology criteria, but integrate them [104]. The same 
issue was raised by the American Thyroid Association 
Clinical Affairs Committee, which concluded that no 
evidence-based recommendation could be made in favor 
or against the use of these methods, but they should be 
used with caution after a careful case-by-case evaluation 
[47]. A projected five-years cost-effectiveness analysis of 
the GEC, estimated that its translation in the clinical 
practice would result in a reduction of approximately 
2,000 USD/patient, in a hypothetical cohort of subjects 
bearing indeterminate thyroid nodules, primarily because 
of the reduction of unnecessary diagnostic surgery [94]. 
Despite the large number of studies recently published on 
this field, especially those comparing new molecular-
based test-methods characterized by rule-out versus rule-
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in approaches [105], there is lack of studies comparing 
these methods with all the others currently available, in 
term of diagnostic accuracy, feasibility, and most 
importantly in term of their cost. Our comparative analysis 
is based on data obtained from different populations in 
different settings and in different Countries and, therefore, 
it should not be considered as a formal comparison among 
cost-effectiveness analyses. Our intention was to perform 
a comparison of the diagnostic abilities and single test cost 
of competing test-methods available, all intended to 
ameliorate thyroid cancer detection among indeterminate 
thyroid nodules. Comparative analysis was performed not 
only using the classical indicators of sensitivity and 
specificity, but also using the likelihood ratios, that have 
been reported to be more useful [87–89]. Considering the 
specific features of each test a diagnostic algorithm for the 
clinical management of indeterminate thyroid nodules was 
recently proposed [31]. According to this flow chart, the 
GEC test-methods should be routinely used to rule-out 
malignancy. However, data reported in the literature and 
the present analysis, clearly indicate that the M/F panel + 
miRNA GEC and M/F by NGS could perform equally well 
in this context. In the same algorithm the use of M/F panel 
has been restricted to confirm malignancy in nodules 
suspicious for malignancy (thy4 according to BTA, tir4 
according to SIE/AIT/AME/SIAPEC and category V, 
according to the Bethesda System), commonly referred to 
surgery, for a more appropriate planning of the extent of 
Figure 7: Algorithm for management of thyroid nodules.
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surgery (i.e. lobectomy vs total thyroidectomy). Although 
some concern has been raised regarding the ability of M/F 
panel to rule-out cancer, because even if the M/F panel 
includes the largest set of known mutations, it is possible 
to detect only a portion of thyroid carcinomas [106], the 
limitation in the use of the M/F panel appears not justified. 
The results of the present comparative analysis clearly 
indicate that M/F panel by NGS, in fact, reached an 
optimal results in term of sensitivity, specificity, likelihood 
ratios, accuracy and DOR and represents the most 
effective test-method that combines the ability in 
excluding (ruling-out) and in identifying (ruling-in) 
thyroid malignancy (Table 3 and Figure 4). The same 
result is obtained when likelihood ratios (Figure 5), 
accuracy (Figure 6) or DOR (Table 3) are considered. 
Interestingly, when the test-methods are analyzed in terms 
of cost and feasibility, the scenario changes. The two new 
molecular-based test-methods, either alone or in 
combination with additional molecular tests, markedly 
differ from the others because their costs exceed the limit 
of 2,000 USD (Figure 5 and Figure 6). Therefore, it seems 
unlikely that these methods will be used as screening test-
methods in the next future, especially in low-income 
Countries [31]. Moreover, for optimal performance these 
molecular assays require centralization in a super 
specialized laboratory. The cost for FDG-PET/CT in 
Europe is approximately 1,132 USD [92]. However, it 
should be emphasized that this technique as well as the 
MIBI-Scan requires a specialized division and a trained 
team of experts. In addition, these exams expose the 
patients to potentially damaging radiations. In this regard, 
it has been calculated by the International Atomic Energy 
Agency (see IAEA, safety reports series no. 58, 2008) that 
the total effective dose for the whole body FDG–PET/CT 
averages 25 mSv, with 8 mSv due to PET and 7-30 mSv 
due to CT scan elements and final diagnostic scan [107]. 
Even if the dose can be lowered by examining only the 
neck, this method appears not suitable as a screening 
method for thyroid nodules population with indeterminate 
cytology. The charge for both BRAF mutation analysis 
and TSHR mRNA blood assay is effectively low, with a 
reported cost of 97.45 and 300 USD/test respectively. 
Considering their good diagnostic performance as rule-in 
tests, they could represent a suitable potential screening 
test for characterizing thyroid nodules with indeterminate 
cytology. However, use of BRAF mutation analysis is 
hampered by a rather low sensitivity. It is expressed in a 
fraction of papillary thyroid cancer (PTC) and in anaplastic 
thyroid cancer arising from PTC as well as in the follicular 
variant of PTC (FVPTC), but not in follicular thyroid 
cancer (FTC) [108, 109]. The indeterminate category is 
mainly constituted of FVPTC, FTC, adenomatoid 
hyperplasia, and follicular adenoma, all of which harbor 
low prevalence of BRAF mutation. It is, therefore, hard 
for BRAF testing to determine malignancy in this category 
of nodules. FVPTC and FTC may therefore represent the 
main source of false-negative results [110]. The published 
data for TSHR mRNA are too preliminary and are affected 
by some selection bias. Pooled cancer prevalence in 
reported studies concerning both BRAF mutation and 
TSHR mRNA were rather high (45% and 44% 
respectively), comparable to the highest value observed 
and reported in South Korea (47.4%) [9], suggesting 
possible selection bias (Table 1). In addition mRNA 
stability in peripheral blood may represent a limitation, 
which could affect the diagnostic accuracy of this specific 
test. There is still need for high quality validation studies 
before recommending the use of this procedure in large 
clinical settings. The clinically validated test-method with 
one of the lowest cost is, indeed, the GAL-3-ICC. The cost 
of this test-method (113 USD/test) is very competitive, 
compared with those estimated for FDG-PET/CT and is 
remarkably low compared to that reported for the 
molecular genetic test-methods (up to 20 times cheaper). 
For this reason it has been previously suggested that GAL-
3-ICC could have a potential screening role, particularly 
in low-income Countries [31]. The present comparative 
analysis shows that GAL-3-ICC performs well both as an 
efficient rule-out and rule-in test-method, with rather good 
likelihood ratios and diagnostic accuracy. As previously 
suggested its clinical utility is, therefore, very high [111, 
112]. Visualization of sensitivity, specificity, likelihood 
ratios, accuracy and, more importantly, cost, in both two- 
and three-dimensional scatterplot diagrams, clearly 
indicates that GAL-3-ICC represents, at the present time, 
the candidate test-method to be chosen on large-scale 
basis. Moreover, GAL-3-ICC uses conventional FNA 
cytological substrates, is very easy to be performed in 
different clinical settings and does not require to be 
centralized in high specialized laboratories. Recently, we 
demonstrated that the sensitivity of GAL-3-ICC can be 
further improved by combination with clinical and 
ultrasound follow-up of negative nodules [93]. For all 
these reasons GAL-3-ICC can be proposed as a screening 
test-method for the preoperative characterization of 
indeterminate thyroid nodules in different clinical settings. 
GAL-3-ICC was recently included in a new algorithm for 
the management of patients with indeterminate FNA that 
was based on four different markers [78]. According to 
this decision model the use of GAL-3-ICC was suggested 
in those indeterminate nodules that were negative for 
BRAF mutation. In addition, to further increase diagnostic 
accuracy, the indeterminate nodules that were negative at 
both BRAF mutation analysis and GAL-3-ICC were 
finally evaluated by real-time RT-PCR assay to detect 
miR-221/miR-222 expression. The proposed original 
sequential combination of these 4 low-cost markers may 
eventually lead to a better definition without increasing too 
much the cost. It is likely that further technical 
improvements of each one of the test-methods considered 
in this analysis, as well as the optimal combination of 
them, will shortly lead to a corresponding increases in the 
overall diagnostic accuracy and cost-effectiveness. Results 
of the present analysis are summarized in a proposed 
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comprehensive algorithm (Figure 7), which differs from 
that previously suggested by Xing [31], because we 
include GAL-3-ICC as the initial screening test-method 
for indeterminate thyroid nodules. In case of negative test, 
the nodule will be monitored and eventually re-biopsied 
during follow-up. In those suspicious cases, in which a 
more accurate exclusion of malignancy is required, an 
additional test, with higher sensitivity/NPV (such as M/F 
panel by NGS and GEC) may be considered. In case of 
positive test, the nodule should be directly referred to 
surgery. However, in high-income Countries, an additional 
test, with higher specificity/PPV (such as the BRAF 
mutation analysis or M/F panel by NGS) may be suggested 
to confirm malignancy and confidently plane in advance 
the extent of surgery.
Considering that the occurrence of indeterminate 
thyroid nodules at conventional cytology has been 
reported in approximately 10-40% of FNA specimens 
[47], the cost saving offered by the proposed GAL-3-
ICC based approach would result significant for Thyroid 
Centers that examine thousands of patients per year, not 
only in low-income countries.
MATERIALS AND METHODS
Literature search and study selection
We performed a systematic review and meta-
analysis on the selected test-methods used for the 
identification of thyroid cancer in indeterminate thyroid 
nodules, following current protocols and guidelines [49]. 
A systematic search was performed on September 9, 2016, 
with PubMed database. We used a search query containing 
a combination of Medical Subject Headings (MeSH) or 
keywords and truncated synonyms (Boolean operators). 
The process of article search and selection is reported in 
a four-phase flow of information diagram, modified from 
that indicated in the PRISMA statement [49] (Figure 1). 
Briefly, PubMed search was initially performed by using 
the following search terms: “thyroid neoplasms”[MeSH 
Terms] OR “thyroid”[All Fields] AND “neoplasms”[All 
Fields] OR “thyroid neoplasms”[All Fields] OR 
“thyroid”[All Fields] AND “cancer”[All Fields] OR 
“thyroid cancer”[All Fields] OR nodule[All Fields] AND 
“diagnosis”[Subheading] OR “diagnosis”[All Fields] OR 
“diagnosis”[MeSH Terms] AND (“biomarkers”[MeSH 
Terms] OR “biomarkers”[All Fields] OR “marker”[All 
Fields] AND hasabstract[text] AND “2000/01/01”[PDAT] 
: “2016/12/31”[PDAT] AND English[lang]. A total of 
29,307 papers were initially retrieved and then further 
reduced to 3,020 using the following additional search 
terms: “Galectin-3” [MeSH Terms], “BRAF mutation 
analysis” [MeSH Terms], “Gene Expression Classifier” 
[MeSH Terms], “FDG-PET/CT” [MeSH Terms], MIBI 
scan [MeSH Terms], “TSHR mRNA” [MeSH Terms] 
and “mutation/fusion panel” [MeSH Terms]. For each 
test-method selected we retrieved available information 
regarding the cost of a single test, as reported below. 
In particular, 259 papers were retrieved using the term 
“Galectin-3”, 1,060 with “BRAF mutation analysis”, 64 
with “Gene Expression Classifier”, 839 with “Mutation/
fusion panel”, 596 with “FDG-PET/CT”, 156 with 
“MIBI-scan” and 46 using the term “TSHR mRNA”. 
Subsequently, another selection criteria was applied 
using the term “Fine Needle Aspiration Cytology” that 
reduced the number of papers down to 83 for Galectin-
3-ICC, to 224 for “BRAF mutation analysis”, to 44 for 
“Gene Expression Classifier”, to 143 for “Mutation Fusion 
Panel”, to 88 for “FDG-PET/CT”, to 26 for “MIBI-scan” 
and to 5 for “TSHR mRNA”. Finally, our comparative 
analysis was performed on those studies that, were chosen 
according to the following inclusion criteria: a) thyroid 
nodule population examined that was classified as thy3a/
thy3f/tir3A/tir3B/III/IV/indeterminate thyroid nodules; 
b) studies that were based on more than 50 indeterminate 
thyroid lesions; c) studies in which all examined patients 
were surgically treated and cytologic reports as well as the 
results of the different test-methods used were verified at 
the final histology; d) validation studies in which patients 
were recruited either in one single or in more than one 
clinical center. Conversely, studies showing the following 
exclusion criteria were not considered in this analysis: a) 
thyroid nodule population examined that was classified 
as suspicious for malignancy (thy4/tir4/V), unequivocal 
cancer at cytology (thy5/tir5/VI) and follicular tumors 
with undefined malignant potential (FTUMP); b) studies 
that were based on less than 50 cases; c) post-validation 
studies in which not all patients were surgically treated 
and/or the final histology was lacking; d) studies in which 
the exact number of true and false positive and negative 
cases wasn’t clearly reported. No specific data have 
been published yet regarding the diagnostic accuracy 
of anyone of the different test-methods examined in the 
new recently proposed nosological thyroid cancer entity, 
named “encapsulated follicular variant of papillary thyroid 
carcinoma” (EFVPTC) [113] that was not included in the 
study. By adopting such criteria we were able to select a 
total of 9 papers for GAL-3-ICC, 24 for BRAF mutation 
analysis, 2 for GEC, 9 for M/F panel, 1 for FDG-PET/CT, 
3 for MIBI-Scan and 2 for TSHR mRNA. Study eligibility 
and quality appraisal of retrieved full-text articles were 
all evaluated and graded independently by 2 investigators. 
Discrepancies were resolved by consensus. All these 
selected studies were included in the present comparative 
analysis.
Analysis of study heterogeneity
The possible occurrence of systematic heterogeneity 
was evaluated in the four test-methods subjected to 
meta-analysis using the forest plot. In order to use the 
appropriate method significance of heterogeneity was 
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preliminary assessed for each method and fixed effect 
model, according to the method of Mantel and Haenszel 
[114] was used for the analysis of BRAF mutation and 
MIBI-Scan selected studies, while random effect model, 
using the method of DerSimonian and Laird [114], was 
applied for the analysis of GAL3-ICC and M/F panel 
selected studies. The estimate of heterogeneity was 
obtained using the Mantel–Haenszel model [114]. The 
software used for meta-analysis was the Stata Statistical 
Software (Release 12, 2011, StataCorp LP, College 
Station, TX) [115, 116].
Analysis of diagnostic test accuracy
Diagnostic performances of the seven different test-
methods considered in the analysis were evaluated by 
applying the basic 2-by-2-table for estimating the diagnostic 
accuracy of a dichotomous or dichotomized quantitative 
test result. Patients with follicular thyroid proliferations 
with and without atypia as well as Hürthle cell follicular 
proliferations were included in the calculations, while 
follicular tumors with undefined malignant potential (FT-
UMP) were excluded from statistical analyses because 
they remain indeterminate also at final histology. For each 
reported test-method sensitivity, specificity, PPV, NPV, 
FPR, FNR, FDR, LR+ and LR-, Cancer risk rate in positive 
test and Cancer risk rate in negative test were calculated, as 
well as three measures of diagnostic test accuracy, namely 
accuracy, F1 score and DOR. The following formulas 
were used for calculations: sensitivity or true positive rate 
(TPR)=TP/(TP+FN), negative predictive value (NPV)=TN/
(TN+FN), cancer risk in negatives test=FN/(FN+TN), 
false negative rate (FNR)=1-TPR, negative likelihood 
ratio (LR-)=(FN/(TP+FN))/(TN/(FP+TN)), specificity 
or true negative rate (TNR)=TN/(TN+FP), cancer risk 
in positives test or positive predictive value (PPV)=TP/
(TP+FP), false positive rate (FPR)=1-TNR, positive 
likelihood ratio (LR+)=(TP/(TP+FN))/(FP/(FP+TN)), 
accuracy=(TP+TN)/(P+N), F1 score=2TP/(2TP+FP+FN), 
and diagnostic odds ratio (DOR)=(TP/FP)/(FN/TN). The 
diagnostic performance values of all studies included in the 
meta-analyses were pooled together.
Comparative two- and three-dimensional 
scatterplot diagrams
In order to comparatively evaluate accuracy, 
sensitivity, specificity and costs of each test-method two- 
and three-dimensional scatterplot diagrams were analyzed 
and visualized using the Stata Statistical Software (Release 
12, 2011, StataCorp LP, College Station, TX) [115, 116] 
and the online visualization option from Plotly [117].
Reported cost of each test-method
A detailed cost effectiveness analysis is available 
for only few methods, while for the others we are able to 
report only the cost of each single test. In particular, for 
Gal-3-ICC a detailed study regarding its cost efficacy has 
not been performed so far. The cost of a single Gal-3-ICC 
test may change in the different context but, as an average 
in Italy, it can be estimated as 100 euro, corresponding to 
113 USD (1 USD = 1.1306 EUR) [90]. A projected five-
years cost-effectiveness analysis of the GEC was published 
in 2011 [94]. According to this study and to another 
recently published study [118], the base case cost of this 
test-method is 3,200 USD. The reported cost of BRAF 
mutation analysis is 475 USD [118, 119]. Combination of 
the cost of this test together with the cost of the GEC alone, 
gives a total price of 3,675 USD. The BRAF medical cost 
is USD 97,45 (range 55-123) according to published 
studies as well as Medicare reimbursement rate [95, 120]. 
A detailed cost-effectiveness analysis of M/F panel applied 
to FNA samples was performed and published [121]. The 
single test cost is 2,250 USD. Medicare reimbursement 
is currently 650 USD, while private reimbursement is 
950 USD [94]. The cost of a single test using the M/F 
panel by NGS was reported to be 3,200 USD [121]. The 
Medicare reimbursement for the TSHR mRNA test is 
300 USD [121]. To date a cost efficacy analysis for this 
method has not been published yet. An accurate cost-
effectiveness analysis of FDG-PET/CT was recently 
published [92]. The mean cost of a single FDG-PET/CT 
in the Netherlands was 1,002 EUR [121], equivalent to 
1,132 USD/test [90] and is similar to that reported in Great 
Britain [122] and in Germany [123]. In the United States, 
the Medicare program provides reimbursement for PET 
and PET/CT. In particular, for examinations performed on 
inpatients or at hospital outpatient departments, a median 
amount of 952.83 USD is reimbursed. The cost as well as 
the radiation exposure, expressed in terms of millisievert 
(mSv), can be lowered if the scan is restricted to the neck 
and focused to the thyroid bed. The reported mean cost 
of a single MIBI-Scan in Germany was 1,459 EUR [48], 
equivalent to 1,648 USD/test [90].
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